• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Metformin ER Recalled Due to Cancer Risk

Metformin ER Recalled Due to Cancer Risk

November 12, 2020
Adam Strassberg, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD. Psychiatrist in private practice, Palo Alto, CA. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Metformin is often prescribed to our patients to prevent weight gain on antipsychotics, but recently the FDA discovered that large batches of various metformin ER formulations may be contaminated with a carcinogen. Voluntary recalls of metformin ER began in May 2020 and have continued to the present. The result is drug shortages, fear, and an unanswered question: Is it still safe to prescribe metformin?


The cause of the recall is NDMA (N-nitrosodimethylamine), not to be confused with the glutamatergic receptor NMDA (N-methyl-D-aspartate). NDMA is a carcinogen that earlier caused the recalls of several popular angiotensin II receptor blockers and the reflux medication ranitidine. NDMA is a common contaminant found in water and foods, especially cured and grilled meats, dairy products, and vegetables. NDMA is genotoxic, and prolonged exposure to elevated levels increases the risk of cancer. However, a person who takes a drug that contains NDMA at or below the FDA acceptable daily limit (96 nanograms) every day for 70 years is not expected to have an increased risk of cancer.


There are many possible sources of NDMA: the drug’s chemical structure, the manufacturing process, the packaging, and even the storage conditions. The exact source of the NDMA impurity for metformin ER remains unknown. To date, FDA testing has not found NDMA in any immediate-release metformin products, so the problem is likely related to the processing of the ER formulation. Branded metformin (Glucophage from Bristol Myers Squibb) has not been affected, although past NDMA recalls have involved both brands and generics.


A searchable list of recalled metformin ER products can be found at this link:
www.fda.gov/drugs/drug-safety-and-availability/search-list-recalled-metformin-products


There is also a “good list” of metformin ER products that were tested and found to have no detectable NDMA:
www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-metformin


The recalled medications can be identified specifically by their National Drug Code (NDC) numbers. The NDC is a unique 10-digit, 3-segment number that identifies the labeler (first segment), the product itself (second segment), and the trade package size (third segment). The NDC should be stamped on your patient’s medication bottle label or the box it came in. You will also need the lot number, as sometimes only certain lots are recalled. This is either on the label printed by the pharmacy or stamped onto the bottle or package itself, where it may or may not be listed as “LOT.” Patients should contact their pharmacy if these identifiers are unclear.


TCPR Verdict: The safest bet is to stick with instant-release metformin until the full extent and cause of this problem is known. If this causes problematic nausea (the main drawback), patients should take it with food. If you do prescribe metformin ER, guide your patient toward a product on the FDA’s “good list.”


podcastsTo learn more, listen to our 11/2/20 podcast, “The Metformin Recall.” Search for “Carlat” on your podcast store.


 

General Psychiatry
KEYWORDS antipsychotics generics metformin weight-gain weight-loss-medications
    Adam Strassberg, MD.

    TMS Treatment for Depression: An Update

    More from this author
    www.thecarlatreport.com
    Issue Date: November 12, 2020
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Practical Psychotherapy, TCPR, November/December 2020
    Is Ramelteon an Effective Hypnotic?
    Side Effects of Psychotherapy
    Brief Therapy During the Medication Visit
    How to Select an SSRI
    Metformin ER Recalled Due to Cancer Risk
    Chemical Exposures
    Beta Blockers and Depression: The Controversy Revisited
    Transcranial Direct-Current Stimulation in Depression Reconsidered
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.